Skip to main content
SpringerLink
Log in

Nilotinib vs dasatinib - nilotinib wins for CML in the real world

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nilotinib vs dasatinib - nilotinib wins for CML in the real world. Pharmacoecon. Outcomes News 620, 6 (2011). https://doi.org/10.2165/00151234-201106200-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201106200-00014

Keywords

Search

Navigation